Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Clene Inc (CLNN)

Clene Inc (CLNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Clene (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025 Investor Brand Network - Tue Jul 8, 11:04AM CDT

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function...

CLNN : 3.59 (-4.52%)
BMWYY : 29.2000 (+4.58%)
Clene (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs Investor Brand Network - Mon Jun 30, 11:38AM CDT

Clene (NASDAQ: CLNN) announced key regulatory developments following a Type C meeting with the FDA, where it received feedback on its statistical analysis plan (SAP) for evaluating neurofilament light...

SAP : 300.85 (-1.75%)
CLNN : 3.59 (-4.52%)
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings GlobeNewswire - Mon Jun 30, 7:00AM CDT

CLNN : 3.59 (-4.52%)
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights GlobeNewswire - Wed May 7, 7:00AM CDT

CLNN : 3.59 (-4.52%)
Clene to Present at the Emerging Growth Conference GlobeNewswire - Mon Apr 14, 7:30AM CDT

CLNN : 3.59 (-4.52%)
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session GlobeNewswire - Tue Apr 8, 7:00AM CDT

CLNN : 3.59 (-4.52%)
Clene (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference Investor Brand Network - Tue Apr 1, 11:10AM CDT

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation...

CLNN : 3.59 (-4.52%)
Clene to Present at the Jones Healthcare and Technology Innovation Conference GlobeNewswire - Tue Apr 1, 7:30AM CDT

CLNN : 3.59 (-4.52%)
Clene’s (NASDAQ: CLNN) Q1 Virtual Investor Summit Available for On-Demand Viewing Investor Brand Network - Thu Mar 27, 11:17AM CDT

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function...

CLNN : 3.59 (-4.52%)
Clene (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data Investor Brand Network - Mon Mar 24, 11:09AM CDT

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, reported a full-year 2024 net loss of $39.4 million, or $5.67 per share, compared to a loss of $49.5 million in 2023. Revenue remained...

CLNN : 3.59 (-4.52%)

Barchart Exclusives

Gold's Bull Run: Seasonal Strength Meets Conflicting COT Report—Are You In? Barchart - Sat Jul 12, 2:47PM CDT
Gold's all-time high $3,509.9! Central banks bought big, but the COT report waves a red flag. Seasonal gains await—Market players, read or regret! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot